Wedge Gastrectomy (Partial / Sleeve of Stomach)

Robotic wedge gastrectomy is the default workflow below; laparoscopic and open approaches are covered as shorter parallel notes. Most commonly done for a GIST or small benign mass. For lymphomas, adenocarcinoma, or hereditary CDH1 syndromes — this is the wrong operation; see the stomach topic review.

Procedure Snapshot

• Indication: Small (< 5 cm), non-ulcerated gastric mass amenable to complete excision with negative margins and without compromising the GE junction or pylorus. Most common: GIST. Also: benign polyps, ectopic pancreas, small carcinoid (well-differentiated Type I / II < 2 cm), leiomyoma, Dieulafoy lesion refractory to endoscopy, small perforation not amenable to omental patch.
• When NOT to do this: adenocarcinoma (needs formal gastrectomy + lymphadenectomy), lymphoma (medical), diffuse gastric process (Ménétrier’s, hereditary), lesion within 2 cm of GE junction or pylorus, lesion causing luminal compromise not fixable with staple line.
• Expected duration: 60–120 min robotic, longer for posterior or high-fundic lesions requiring lesser-sac entry.
• Positioning: Supine, arms tucked, split-leg or reverse-Trendelenburg. Foley. Orogastric tube — remove before firing the stapler across the stomach.
• Prep: Cefazolin within 60 min of incision. NPO overnight. Confirm mass location on preop imaging + endoscopy report.
• Robotic platform: da Vinci Xi.
• Special instruments: SureForm 45 blue reloads (or Endo GIA 45 blue in lap), bipolar fenestrated, vessel sealer (Maryland or Vessel Sealer Extend), Cadiere grasper, needle driver, robotic suction irrigator (only if planning intra-op EGD leak test), Carter–Thomason for 12 mm port fascial closure. Blue bougie available if lesion approaches the antrum/incisura and you’re worried about lumen narrowing.
• Endoscopy: Have EGD available on the field — intra-op scope confirms lesion location on wedges done for indistinct posterior masses, and enables an air-leak test if desired.

---

Step Workflow — Robotic Wedge Gastrectomy (primary)

1. Positioning, Ports, Docking
   • Supine, split-leg, reverse Trendelenburg to let small bowel fall away from the stomach.
   • Five-port setup across the upper abdomen, patient right to left:
     • 8 mm robotic port — bipolar fenestrated grasper (left hand).
     • 8 mm robotic port — camera.
     • 12 mm assistant/robotic port — this is your working port; the vessel sealer goes here first, then the robotic stapler, then a needle driver depending on the step. Sized 12 mm so the SureForm 45 fits.
     • 8 mm robotic port — right hand (energy, needle driver alternately).
     • 8 mm robotic port — Cadiere grasper for stomach retraction.
   • Dock the Xi over the patient’s left shoulder / head; boom targets the epigastrium.
2. Exposure and Initial Survey
   • Elevate the left lateral segment of the liver with a Nathanson-style retractor or a locked Cadiere on the falciform.
   • Inspect the anterior gastric surface. If the lesion is anterior and easily palpable/visible, skip step 3.
3. Access to Posterior Gastric Wall (if lesion posterior or intramural)
   • Open the greater curvature with the vessel sealer along the gastroepiploic arcade, taking short gastric branches as needed to enter the lesser sac.
   • Retract the stomach anterior and superior with the Cadiere to expose the posterior wall.
   • Alternatively — for a lesion near the lesser curvature — open the gastrohepatic ligament and access the lesser sac medially.
   • If the mass is still not localizable, bring EGD to the field: transilluminate through the wall or grasp the endoscopically-visible lesion with a robotic grasper from outside to mark the epicenter.
4. Wedge Excision with Linear Stapler
   • Position the stomach so the intended staple line runs transverse to the long axis of the stomach whenever possible — reduces risk of luminal narrowing.
   • Fire SureForm 45 mm blue loads across the base of the lesion, taking wide (~1 cm) macroscopic negative margins. GISTs need R0 but do not require the 4 cm oncologic margin of adenocarcinoma.
   • Sequential fires as needed to encircle the mass. Minimize the number of firings — each additional fire raises the leak risk and creates intersecting staple lines. Ideal is one to two fires.
   • If the lesion is near the antrum/incisura, place a blue bougie trans-orally before stapling to guarantee luminal patency. Fire the stapler over the bougie.
   • Oversew corners and any bleeding staple line points with 3-0 Vicryl on an SH needle. Two Lembert-style reinforcing bites at each staple-line corner is standard.
5. Specimen Handling and Optional Leak Test
   • Place the specimen in a small endocatch bag.
   • Optional intra-operative EGD leak test: insufflate the stomach through the scope while the pylorus is atraumatically clamped and the staple line submerged in saline via robotic suction irrigator. Any bubbles → oversew the visible defect and retest.
   • Retest until dry.
6. Extraction and Closure
   • Extract the specimen through the 12 mm port site. Extend fascia only if truly needed (unusual for a wedge).
   • Close the 12 mm port fascia with a Carter–Thomason device under direct vision, 0 Vicryl.
   • 8 mm port skin closure with 4-0 Monocryl subcuticular; skin glue or Steri-Strips.

---

Step Workflow — Laparoscopic (parallel option)

• Same operative principles. Five-port setup similar to robotic — but with 5 mm working ports where possible and one 12 mm port for the Endo GIA 45 blue reload / specimen extraction.
• Harder for posterior masses without articulating instruments; consider intra-op EGD earlier to localize.
• Endo GIA 45 blue substitutes for SureForm; needle-driver oversewing is harder ergonomically — many surgeons rely on staple-line hemostasis alone in lap.

Step Workflow — Open (parallel option)

• Upper midline laparotomy. Reserved for prior hostile abdomen, very large mass, or conversion.
• Same staple-line technique with a TA-90 or GIA-60 blue reload.
• Hand-sewn primary closure is also an option — inner running 3-0 Vicryl, outer interrupted 3-0 silk Lembert.
• Higher SSI and ileus vs MIS.

---

Rapid-Fire Questions

• Q: Most common indication for wedge gastrectomy? A: Gastric GIST, especially small (< 5 cm), well-circumscribed, exophytic tumors.

• Q: How much margin do you need for a gastric GIST? A: R0 (negative microscopic margin). Unlike adenocarcinoma, GIST does not require a specified cm margin; a wedge with 1 cm gross margin that is R0 pathologically is adequate. Lymphadenectomy is not required — GISTs rarely go to nodes.

• Q: Why not wedge an adenocarcinoma? A: Adenocarcinoma requires ≥ 4 cm margins and a D1 or modified D2 lymphadenectomy (station 1–6 for D1, adds 7–11 for D2). A wedge cannot deliver either.

• Q: Wedge is not appropriate for a lesion where? A: Within 2 cm of the GE junction (risk of stenosis / need for anastomosis) or within 2 cm of the pylorus (gastric outlet obstruction). Also inappropriate for diffuse or ill-defined lesions.

• Q: Stapling near the incisura — what do you do to protect the lumen? A: Place a bougie (blue bougie set is standard) trans-orally down to the antrum and fire the stapler over the bougie so the residual lumen is calibrated.

• Q: How do you orient the staple line? A: Transverse to the long axis of the stomach wherever possible — minimizes narrowing. A longitudinal staple line risks turning the stomach into an unintended sleeve.

• Q: What is the pathologic risk stratification for GIST? A: Miettinen–Lasota criteria: based on size (≤ 2, 2–5, 5–10, > 10 cm), mitotic count (≤ 5 vs > 5 per 50 HPF), and location (gastric better prognosis than small bowel). Very small (< 2 cm) low-mitotic gastric GISTs are essentially benign.

• Q: Who gets adjuvant imatinib after GIST resection? A: Intermediate- or high-risk GIST (size ≥ 3 cm, high mitotic count, non-gastric location, or rupture at surgery) → adjuvant imatinib for ≥ 3 years. Small low-risk gastric GISTs need observation only.

• Q: Most common mutation in GIST? A: KIT (CD117) gain-of-function mutation, ~75%. PDGFRA ~10%. The remainder are wild-type / SDH-deficient. IHC for CD117 confirms the diagnosis; PDGFRA D842V is imatinib-resistant.

• Q: Posterior gastric mass — how do you get to it robotically? A: Open the greater curvature along the gastroepiploic arcade with a vessel sealer to enter the lesser sac, then retract the stomach anterior and superior with the Cadiere to expose the posterior wall. Alternately open the gastrohepatic ligament from above.

• Q: Intra-op you can’t find the lesion — what do you do? A: Bring EGD to the field. Transilluminate through the wall or grasp the endoscopically-visible lesion externally with a robotic grasper to mark the epicenter. Do not resect blindly.

• Q: Do you need to test the staple line? A: Optional but wise for larger resections or resections near the incisura. Insufflate via EGD with the pylorus atraumatically occluded and the staple line submerged in saline — look for bubbles. Alternative: methylene blue via OGT.

• Q: Which port do you close and how? A: The 12 mm port fascia — Carter–Thomason device with 0 Vicryl under direct vision. The 8 mm robotic ports do not require fascial closure per manufacturer guidance.

• Q: Ruptured GIST at time of surgery — what does that change? A: Automatic high-risk classification (increases peritoneal dissemination risk substantially). Full course of adjuvant imatinib is indicated regardless of size or mitotic count.

---

Critical Anatomy

• Vascular supply of the stomach (five arteries): left gastric (celiac → lesser curve), right gastric (common hepatic / proper hepatic → lesser curve), left gastroepiploic (splenic → greater curve), right gastroepiploic (gastroduodenal → greater curve), short gastrics (splenic → fundus). All five can be sacrificed and the stomach will still perfuse — but for a wedge you only take what’s needed to expose the lesion.
• Gastroepiploic arcade — the greater-curvature vessel used to enter the lesser sac. Sealed with vessel sealer / harmonic in bite-sized takes.
• Lesser sac — bounded by stomach anteriorly, pancreas posteriorly, gastrocolic ligament inferiorly, gastrohepatic ligament / porta hepatis medially. Entry is required for posterior gastric wall access.
• GE junction — proximally, no wedge within 2 cm. Recognize by fat pad, angle of His, and endoscopic transillumination if uncertain.
• Pylorus — distally, no wedge within 2 cm. Palpate the muscular ring.
• Danger zones:
  • Splenic hilum / short gastrics when working near the fundus.
  • Left gastric artery when working near the lesser curvature high on the stomach.
  • Common bile duct when accessing the gastrohepatic ligament — usually protected but worth identifying.
  • Transverse mesocolon when entering the lesser sac from below — do not injure the middle colic vessels.

---

Informed Consent Highlights

• Risks:
  • Staple-line bleed ~ 1–3%; may require re-look, over-sewing, or endoscopic clipping.
  • Staple-line leak ~ 1–2% (higher near incisura or GE junction); may require drainage, endoscopic stent, or reoperation.
  • Gastric outlet obstruction if lesion too close to pylorus — hence bougie technique.
  • Positive margin (R1/R2) requiring re-resection or systemic therapy.
  • Injury to adjacent structures: spleen (~1%, especially with fundic lesions), pancreas, colon, common bile duct.
  • Conversion to open ~ 2–5%.
  • Standard: bleeding, SSI, DVT, cardiopulmonary, death.
• Benefits: Complete excision with organ preservation; minimally invasive recovery.
• Alternatives:
  • Endoscopic resection (ESD/EMR) for very superficial mucosal lesions — not appropriate for full-thickness GIST or lesions extending into muscularis propria.
  • Formal gastrectomy — required for adenocarcinoma, large tumors, or diffuse disease.
  • Observation for small (< 2 cm) asymptomatic gastric GIST with low mitotic index — EUS surveillance is acceptable per NCCN.
  • Neoadjuvant imatinib for larger GIST (> 5 cm), potentially shrinking to a wedge-amenable lesion.

---

Post-Op Considerations

• Diet: Clear liquids on POD 0 once alert; advance to soft/regular over 24–48 h.
• Foley: Out on POD 1.
• NG tube: Not routinely placed. Remove OGT before extubation.
• Analgesia: Multimodal, opioid-sparing. TAP block if desired.
• VTE prophylaxis: LMWH; continue 4 weeks post-discharge for cancer.
• Discharge: Typically POD 1–2 for uncomplicated robotic wedge.
• Follow-up:
  • Wound check at 2 weeks.
  • Pathology review to confirm R0 and to stratify risk (Miettinen–Lasota).
  • Medical oncology for adjuvant imatinib if intermediate/high risk.
• Red flags:
  • Persistent tachycardia, fever, or rising WBC on POD 3–5 → CT with oral contrast to rule out leak or abscess.
  • Persistent vomiting → obstruction from staple-line stenosis; consider UGI series and endoscopy.

---

Clinical Pearls

• Orient the staple line transverse to the long axis of the stomach whenever geometry allows — a longitudinal firing narrows the lumen.
• Blue bougie down before firing near the incisura or antrum. Cheap insurance against gastric outlet obstruction.
• Oversew the two staple-line corners with 3-0 Vicryl — these are the classic bleed and leak nidus, same idea as the LAR anvil-through-edge principle. Bury the vertex.
• Bring EGD to the field for any indistinct lesion. Do not blind-wedge.
• Take short gastrics if you need fundic mobility — the stomach still perfuses.
• Do not mobilize more than you need. Leave the omentum, greater curvature vessels, and hepatogastric ligament intact when possible. Preservation makes future surgery easier.
• The 12 mm port fascia gets Carter–Thomason. Every time. 8 mm port fascia does not.
• GIST is not adenocarcinoma. Don’t do a lymphadenectomy.
• If the lesion ruptures intra-op → prep for open, take a photo for path, plan a full course of adjuvant imatinib.

---

Quick Reference Table

---

Quick-Reference Cards

---

Related Topic Reviews

• Stomach — anatomy, ulcers, cancer, GIST, neuroendocrine tumors, post-gastrectomy syndromes.

Related Landmark Papers

• STITCH — small-bites fascial closure at the extraction site.

---

References

1. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012; 13(3): 265–274.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2): 70–83.
3. Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guideline. Ann Oncol. 2022; 33(1): 20–33.
4. NCCN Clinical Practice Guidelines in Oncology — Soft Tissue Sarcoma, GIST section. NCCN.org.
5. Deerenberg EB, Harlaar JJ, Steyerberg EW, et al. Small bites vs large bites for closure of abdominal midline incisions (STITCH). Lancet. 2015; 386(10000): 1254–1260.